
usd apr pm et
summari water corpor manufactur scientif analyt equip liquid
chromatographi mass spectrometri thermal analysi product
price-to-earnings oper ep
past perform indic futur perform reli upon
analysi prepar equiti analyst
apr stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
et cfra maintain
corpor cut target
price ep
estim wat five-year histor
forward price-to-earnings averag follow faster
anticip sale declin due
pandem could
exacerb follow quarter cut
ep estim
ep estim ep
vs yoy
consensu estim push stock price
yesterday revenu
yoy due mainli reduc
demand china chines sale
total yoy although less
dramat sale declin due
observ across geographi asian sale
yoy america yoy
sale europ yoy think
impact felt later
quarter expect challeng
think contain measur
extend neg impact major
market europ /sel
risk assess reflect strong brand power
liquid chromatographi mass spectrometri thermal
analysi market gener highest margin
industri advantag partial off-set howev
highli competit marketplac depend
pharmaceut budget revenu
drug firm produc volatil sale swing
instrument maker budget manufactur
need unexpectedli face larg cut also carri
product risk escal tariff environ
view product capac locat
jul ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview water corpor specialti measur compani develop tool
liquid chromatographi lc mass spectrometri ms thermal analysi ta tool primarili
serv research develop manufactur tester life materi food scienc
compani also sell softwar platform use oper machin analyz result data well
servic laboratori workflow optim
liquid chromatographyi standard scientif techniqu separ identifi constitu
compon variou compound molecular level lc allow research analyz chemic
physic biolog composit materi liquid chromatographi often use tandem
mass spectrometri use elucid structur chemic properti molecul
measur mass molecul convert ion ms also use identifi
quantifi amount specif compound present sampl
thermal analysi tool allow research analyz compound react temperatur chang
especi electr properti chang physic properti fluctuat weight flow
characterist thermal analysi use help research predict compound perform
move laboratori state applic state molecul drug
perform blood rather lab bench suitabl stabil fine
chemic pharmaceut water polym metal viscou liquid use industri applic
consum good health care product better understood thermal analysi
import user product research pharmaceut life scienc
industri scientist use lc ms ta extens analyz compound molecular level
help better understand diseas discov new drug develop manufactur method assur
potenc puriti new pharmaceut tool also use varieti applic
analyz content food beverag nutrit label complianc test water
air sampl meet safeti puriti regul within environment test busi well
applic industri chemic consum product univers research
institut government agenc food drug administr fda
environment protect agenc epa foreign counterpart also frequent user
import aspect busi understand instrument sale vs consum servic
sale instrument perman fixtur laboratori manufactur site come rel
larg up-front cost convers consum lower-cost product use analyz
instrument typic replac regular interv relationship instrument
consum somewhat analog razor razor-blad model custom typic purchas
rel small number instrument continu order larg volum consum
life machin analyz thousand sampl instrument sale often lead recur
softwar servic contract revenu well way singl instrument sale often lead durabl
long-term sale lower-cost product mitig cyclic instrument sale
revenu came instrument servic consum
breakdown sale geographi follow asia america europ
differ sale growth yoy sale declin yoy mainli driven europ
yoy due challeng econom condit moreov rel modest growth
yoy could off-set signific contract america ex yoy push
america region contract yoy asia wit sharp slowdown growth slow
yoy yoy due contract seen china yoy
deceler growth compar yoy growth period previou year
explain slowdown econom activ china view except exacerb
us expect cautiou tone wit custom seen far remain
competit landscap due often high-tech innov natur custom
must also frequent innov product meet evolv custom need stay competit
spent revenu research develop
competit market tool intens rival compet primarili basi
product innov perform reliabl servic price lc ms market competitor
includ larg life scienc tool servic firm shimadzu
thermo fisher scientif thermal analysi market princip competitor includ
panalyt anton-paar
financi trend sale increas repres three-year
compound annual growth rate compound-annual-growth-rate gross profit margin remain rel
constant around respect grown ep materi faster
revenu combin improv oper margin share count reduct adjust ep
rose three-year compound-annual-growth-rate compani execut net share
repurchas worth reduc share count three-year
period maintain low debt rel earn net debt/ebitda decemb
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
overvalu usd
neutral sinc april technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
neutral fundament outlook
life scienc tool servic sub-industri
expect earn growth remain
posit slow sharpli rate achiev
risk factor see slower
biopharmaceut spend growth
prolong uncertainti due
nation institut nih budget
grow rapidli last three
year materi increas fund
academ govern lab turn
help drive sale growth mani lst
compani suppli lab nih fy
sep budget grew vs prior year
follow growth fy
mark major acceler averag growth
fy fy believ
boost sale lst
sub-industri grew
prolifer advanc health care around
world continu drive demand growth
lst firm long-term emerg
market particularli china india
rapidli grow middl class gain
access advanc health care
drive suppli need new expand
medic research lab facil howev
due rapidli spread coronaviru
result suppli chain travel disrupt
expect slowdown demand next
think biopharmaceut firm moder
 spend growth due
outbreak
estim total spend
global biopharmaceut compani grew
annual averag expect slow
see
delay new clinic trial halt
on-go studi major pharmaceut
compani larg swath biopharma
typic flow lst firm suppli
depart research tool softwar
contract servic accordingli think
slowdown biopharma growth
reduc tailwind mani lst firm
receiv client group recent
expect recent coronaviru outbreak
oper result first half
china small promis market
lst compani around total
sector revenu seen number
disrupt due travel restrict
temporari closur site china
expect loss stem chines
oper limit expect
loss increas
time certain lst compani
well-posit benefit outbreak
close work
govern hospit develop test
kit sequenc genom viru
fda issu emerg author
number lst firm diagnost
serolog test use
laboratori detect
consider need respond grow
daili diagnost demand point
 lst compani quickli
absorb demand
year date april
servic declin compar
decreas experienc
broader healthcar sector
decreas overal
index life scienc tool
much faster rise
healthcar sector rise
base index
five-year market price perform apr
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
scientif inc maintain price target ep
estim share major analyt instrument maker
sharpli today includ
around midday believ sell-off partial
relat ad chines firm export blacklist monday
increas tension trade war view hurt global
suppli chain instrument maker disagre reaction share
howev think compani global divers product facil
uniqu lack single-sourc suppli relationship give much greater flexibl
peer avoid tariff-driven cost increas view advantag
actual allow take signific instrument market share smaller firm
like etc reli china revenu
wherea gener roughli sale /colin scarola
pm et cfra maintain sell opinion share water corpor
keep target ep estim --
histor forward price-to-earnings averag lower ep estim
maintain ep vs beat consensu
pharmaceut sale total grew yoy off-set declin
industri academ govern sale europ
revenu especi weak reflect slowdown econom growth
region view also think rel weak posit
trade war display pre-tax margin basi point
yoy driven view high concentr -focus product
sale intern mitig impact lower
sale higher cost repurchas see
sustain free cash flow declin co cash pile sinc
decemb also see sharp rise inventori bode poorli futur
analyst research note compani news
et cfra maintain hold opinion share water corpor
cut target price ep
estim wat five-year histor forward price-to-earnings averag
follow faster anticip sale declin due
pandem could exacerb follow quarter cut
ep estim ep estim
ep vs yoy
consensu estim push stock price yesterday
revenu yoy due mainli reduc demand china
chines sale total yoy although less dramat sale
declin due observ across geographi asian sale
yoy america yoy sale europ yoy think
impact felt later quarter expect
challeng think contain measur extend
neg impact major market europ /sel hardi
et cfra maintain hold opinion share water corpor
lower target price ep
estim wat five-year histor forward price-to-earnings averag due
increas risk face chines oper follow coronaviru outbreak
trim ep estim impli yoy
growth expect continu post slow revenu growth
maintain ep estim ep vs ep
better consensu view revenu flat
in-lin wat guidanc due mainli decreas yoy core
instrument segment total result soft china ta
brand instrument sale yoy off-set yoy
increas servic total chemistri total continu
maintain mix view despit solid momentum servic
chemistri busi expect declin chines sale total
due coronaviru outbreak /sel hardi
et cfra lift sell opinion share water corpor hold
lift target ep estim
line five-year histor forward price-to-earnings averag
maintain ep estim
think one best-posit name within life scienc
sphere benefit resolut phase-on deal
china although uncertainti remain detail agreement
view risk relat revenu slowdown america due
cautiou tone wit custom europ due challeng
econom condit yet risk could off-set renew growth
momentum china wit double-digit growth across product
custom segment experienc subdu growth yoy
first nine month thu prefer neutral see clear
posit neg wat financi perform /sel hardi
pm et cfra maintain sell opinion share water corpor
keep target ep estim --
histor forward price-to-earnings averag lower ep estim
start ep vs
met consensu revenu flat yoy miss guidanc
yoy drop instrument sale total weigh result america
revenu fell yoy sharp slowdown growth
instrument peer like continu gener strong growth
year though lead us believ lose market share due
view less flexibl manag tariff less sticki custom due
narrow product line ytd adjust pre-tax incom yoy
kept adjust ep grow ytd share repurchas
increas restructur adjust sustain sourc
ep growth view especi cash avail repurchas
low /colin scarola
pm et cfra maintain buy opinion share thermo fisher
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
